Skip to main content

Table 2 Demographic data, exposure characteristics, and lung function tests according to latency period

From: The association of human leukocyte antigen polymorphisms with disease severity and latency period in patients with silicosis

 

Short latency**

Long latency***

P

Mean

Subjects n

23

25

-

-

Age (years)

22.4 ± 7.2

23.4 ± 8.5

-

NS*

BMI

21.7 ± 3.1

22.6 ± 2.6

-

NS*

Total exposure duration (months)

21.4 ± 13.9

38.0 ± 27.4

0.012

Significant

Latency period (months)

37.9 ± 17.6

73.0 ± 16.6

0.001

Significant

Smoking (pack/years)

3.9 ± 4.4

8.1 ± 6.5

0.014

Significant

FEV1 L

3.7 ± 0.6

3.3 ± 0.9

-

NS*

FEV1% pred

95.0 ± 18.7

83.4 ± 24.6

-

NS*

FVC L

4.4 ± 0.8

3.9 ± 1.0

-

NS*

FVC% pred

96.6 ± 19.3

83.5 ± 25.1

0.05

Borderline

FEV1/FVC%

84.3 ± 7.3

83.1 ± 9.4

-

NS*

  1. *NS, Not significant; **Short latency, cases whose latency periods are ≤ 50 months. ***Long latency, cases whose latency periods are > 50 months.